Now that the Senate Finance Committee has passed its version of the health care reform bill, the generic-drug industry will begin lobbying lawmakers on provisions that could determine how quickly generic versions of biologic drugs can be marketed. Brand-name biologic manufacturers want to hold off generics for 12 years, but generics makers argue the time frame should be reduced to no more than seven years to reduce health care spending. "The current bill is not going to provide needed access to affordable lifesaving medicines," the president of the Generic Pharmaceutical Association said.

Related Summaries